Enanta Pharmaceuticals | ENTA - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Amgen USD 11.69B 6.9B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Immunic USD 23.33M 2.67M 2025-12
Incyte USD 973.64M 4.65B 2026-06
Insmed USD 526.79M 20.55M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
J&J USD 17.83B 388M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Merck USD 15.77B 2.4B 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Roche Holding CHF 18.9B 2.12B 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06